Molecular Partners Showcases Nature Cancer Phase 1 Data and Advances MP0317 Into Phase 2 Cholangiocarcinoma Trial

Molecular Partners ( (MOLN) ) has shared an update.

On May 1, 2026, Molecular Partners reported that Phase 1 monotherapy data for its tumor-localized CD40 agonist MP0317 have been published in the journal Nature Cancer, showing proof-of-mechanism via CD40 activation anchored to fibroblast activation protein in the tumor microenvironment and a favorable safety profile up to the highest tested dose. In the 46-patient study of advanced solid tumors, investigators observed one unconfirmed partial response and 14 cases of stable disease, while pharmacokinetics indicated MP0317 is suitable for weekly or three-weekly dosing and potentially well matched for combination use, underscoring its role in Molecular Partners’ strategy to differentiate in immuno-oncology.

The company also highlighted ongoing clinical expansion with an investigator-initiated, randomized Phase 2 trial of MP0317 in front-line advanced cholangiocarcinoma, combining the drug with standard-of-care durvalumab plus gemcitabine-cisplatin versus standard-of-care alone at eight active sites in France. By targeting tumor microenvironment remodeling to convert so-called “cold” tumors into “hot” ones, the program positions Molecular Partners to potentially enhance outcomes in a hard-to-treat cancer and, if successful, could strengthen its competitive standing in immunotherapy combinations and support broader development of its DARPin platform.

The most recent analyst rating on (MOLN) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Spark’s Take on MOLN Stock

According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.

The score is weighed down primarily by collapsing revenue and persistent cash burn (weak financial performance), with additional pressure from negative technical momentum (below key moving averages with negative MACD). Valuation is also constrained by losses (negative P/E) and no dividend support.

To see Spark’s full report on MOLN stock, click here.

More about Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company developing a novel class of protein drugs called DARPin therapeutics to address medical challenges not readily served by existing modalities, with a focus on oncology. The company’s pipeline spans targeted radiopharmaceuticals and next-generation immune cell engagers, comprising proprietary programs and collaborations with major pharmaceutical partners across pre-clinical and clinical stages.

Average Trading Volume: 3,438

Technical Sentiment Signal: Sell

Current Market Cap: $165.8M

See more data about MOLN stock on TipRanks’ Stock Analysis page.